ABSTRACT

The study evaluates oxidative stress (OS) in patients with different stages of periodontal disease (PD) and the influence of their smoking habits on OS. PD is related to connective tissue inflammation, which leads to deterioration of the supporting structures of the tooth. OS is a condition characterised by overproduction of free radicals (FR), which may be involved in PD, causing periodontal tissue damage and other related diseases. Study patients’ were grouped as I-non smokers (n=45) and II-smokers (n=45); and consisted of patients with 3 PD stages: mild (1), moderate (2) and severe (3). As a control group, 30 healthy subjects (all non smokers) with no signs of PD were selected. FR levels were determined by the D-Roms test, total antioxidant capacity (AOC) was determined by the OXY-adsorbent test, (Diacron, Italy) and lipid peroxidation (LP) was determined by the fluorometric method with thiobarbituric acid and its end product, malonildialdehyde (MDA). OS was found in the periodontal tissue and serum of PD patients, with the highest level of FR in the severe stage (3) in non smokers (p<0.05) as well as smokers (p<0.01); AOC showed decreasing values from mild (1) to severe stage (3) of PD for smokers (p<0.05). LP in serum showed the highest level in severe stage (3) in both groups i.e., non smokers and smokers (p<0.05) compared to controls.

Based on the obtained results, we may conclude that PD is related to OS and may either be a cause or a trigger for more accelerated OS. Cigarette smoking increased FR production and is a serious factor exacerbating further tissue damage in PD. These findings may contribute to possible use of efficient antioxidant agents as a preventive measure for PD and as a therapy for better disease outcome.

Key words: periodontal disease, oxidative stress, smoking.

SAŽETAK

Ova studija se bavi procenom oksidativnog stresa (OS) kod pacijenata sa različitim stadijumima oboljenja paradontopaža - paradontopatija (PD), i uticaja pušačkih navika pacijenata. PD je povezana sa zapaljenjem vezivnih tkiva koje uzrokuje oštećenje tkivnog oslonca zuba. OS je stanje koje nastaje usled prevelike produkcije slobodnih radikala (SR) koji mogu biti uključeni u patogenezu PD, uzrokujući oštećenje paradontalnih tkiva i drugih bliskih tkiva. Pacijenti su bili podeljeni u sledeće grupe: I – nepušači (n=45), II - pušači (n=45); i consist of patients with 3 PD stages: mild (1), moderate (2), and severe (3). As a control group, 30 healthy subjects (all non smokers) with no signs of PD were selected. FR levels were determined by the D-Roms test, total antioxidant capacity (AOC) was determined by the OXY-adsorbent test, (Diacron, Italy) and lipid peroxidation (LP) was determined by the fluorometric method with thiobarbituric acid and its end product, malonildialdehyde (MDA). OS je detektovan u tkivu i serumu pacijenata sa PD: SR su pokazali najviši nivo kod pacijenata sa teškim stadijumom PD u grupi nepušača (p<0.05) i pušača (p<0.01); vrednosti LIAK su se smanjivale od blagog (1) do teškog stadijuma (3) PD u grupi pušača (p<0.05), LP u serumu je imala najviši nivo u teškom stadijumu PD, i u grupi pušača i u grupi nepušača (p<0.05).

Na osnovu dobijenih rezultata možemo da zaključimo da je PD povezana sa OS, i može biti jedan od uzroka ili pokretačkih mehanizama za dinamičnije povećanje OS. Pušenje cigareta povećava nastajanje SR, i predstavlja značajan faktor daljeg oštećenja tkiva u PD. Ovi rezultati mogu da doprinese mogućoj upotrebi antioksidativnih preparata u prevenciji PD, kao i terapiji, u cilju postizanja boljeg ishoda bolesti.

Ključne reči: paradontopatija, oksidativni stres, pušenje.
INTRODUCTION

The periodontal complex comprises alveolar bone, periodontal ligament, root cementum and the gingival tissue, all of which are crucial supporting structures of the tooth. Periodontal disease (PD) is characterized by chronic inflammation of the connective tissue leading to bone damage, which can be attributed to an impaired immune system. PD has also been linked to oral cancer, heart disease, stroke, osteoporosis, pre-term births, diabetes, and respiratory infections. Neutrophils that have been sequenced in the connective tissue and gingival sulcus attack bacteria and release enzymes that cause cell destruction, triggering oxidative stress (OS) by free radical (FR) production (1, 2). Internally generated FRs are from sources such as mitochondria, phagocytes, cytochrome P-450 reactions, peroxisomal fatty acid metabolism, xanthine oxidase and inflammation, where sources of externally generated FRs are cigarette smoking, air pollution, radiation, ultraviolet lights, chemicals, toxins, pathogenic microorganisms, etc. (3). Oxygen uptake in neutrophils is based on the flavin-dependent cytochrome oxidase system, which increases NADPH production via hexose monophosphate shunt. Thus, it generates FRs such as superoxide anions, hydrogen peroxide, hydroxyl and hypochlorous acid. Due to unpaired electrons in the FR structure, they are highly reactive substances. Consequently, they are able to attack and damage cells by affecting lipids, proteins, carbohydrates and DNA molecules. They are capable of damaging either the cell membrane or certain bio-molecules, which leads to lipid peroxidation (LP), protein and DNA damage, enzyme oxidation and cytokine release (4). If the antioxidant capacity (AOC) is not sufficient to prevent and treat the cell impairment with the help of antioxidant enzymes, antioxidant molecules and some repair enzymes (5, 6), irreversible pathological processes may occur. This process may be accelerated by cigarette smoking, which has a likely role in periodontal disease progression. Severity of the disease may be proportional to the intensity of smoking (7). In addition to PD (8, 9, 10), OS has been implicated in the pathogenesis of a number of diseases, such as diabetes mellitus, cardiovascular (11) and neurodegenerative diseases (12) and malignancies (13). The aim of this study was to evaluate OS in patients with different stages of PD and the influence of their smoking habits on OS.

MATERIAL AND METHODS

Ninety patients with PD aged 37±15 years were divided into 2 groups: group I (n=45) included patients who did not smoke cigarettes and group II (n=45) included patients who smoked cigarettes. As a control group, 30 healthy subjects (all non smokers) with no signs of PD were selected. Both patient groups were divided into 3 subgroups of 15 patients each, representing the 3 different disease stages, i.e., mild, moderate and severe PD, classified on the basis of anamnesis, clinical and roentgenographic examination. The clinical examination was performed using the dental plaque index based on the scale of Loe & Silness, 1963 (14) to score the disease stage from 0 to 3 as follows: stage 0 - normal periodontal tissue, without plaque, which constituted the control group; stage 1 - mild inflammation with slight colour changes in periodontal tissue, slight edema and no bleeding on probing; stage 2 - moderate inflammation with redness, edema, glazing on probing and presence of plaque in periodontal pocket, evident by visual examination; and stage 3 - severe inflammation with marked redness and edema, ulceration and tendency to spontaneous bleeding.

None of the patients had any detectable chronic disease, such as renal and liver failure or cardiovascular disease, or any other infection, neither were they given any medications. Roentgenographic examination confirmed the determined stage of PD and together with clinical examination and anamnesis contributed to the precise disease stage distinction. For laboratory testing, periodontal tissue and serum were used. The samples were taken during periodontal surgery in the course of normal treatment. After withdrawal, periodontal tissue was first measured, followed by addition of 1 ml phosphate buffer and storage at a temperature of -80°C. The samples were homogenised for 5 minutes in Microson ultrasonic cell disruptor and centrifuged for 5 minutes at 5000 rpm. For serum, blood sample from cubital vein was centrifuged for 10 minutes at 3000 rpm and stored at -4°C.

FRs were measured using the spectrophotometric method based on the D-Roms test, AOC was measured using the OXY-adsorbent test (Diacron, Italy), and LP was determined by its end product malondialdehyde (MDA) using the modified fluorometric method with thiobarbituric acid (Ohkawa at al, 1978) (15). The degree of LP in serum and periodontal tissue was estimated by the modified fluorometric method, measuring thiobarbituric acid reactive substances (TBARS) using 1 % TBA (Thiobarbituric acid) in 0.05 NaOH incubated with serum and periodontal tissue at 100 °C for 15 min and read at 530 nm. Krebs-Henseleit solution was used as a blank probe.

For the statistical analysis, a Student t-test was used, and statistical significance was considered for p<0.05.

RESULTS

In the control group, FRs showed higher values in serum (293±68 U.Carr) than in periodontal tissue (220±53 U.Carr) (p<0.05). However, no difference was found in AOC between periodontal tissue (338±63 μmolHClO/ml) and serum (342±67 μmolHClO/ml) in the control group. The level of LP in serum was 3.5±0.9 μmol/l in the control group. All obtained values in control group were considered as reference values (Table 1, 2, 3).

OS was found in both the periodontal tissue and the serum of PD patients. In the periodontal tissue, production
of FR progressively increased from mild, i.e., stage 1, to severe, i.e., stage 3 of PD. It showed the highest level in stage 3 in both patient groups: non smokers (440±88 UCarr) (p<0.05) and smokers (528±90 UCarr) (p<0.01). The AOC of periodontal tissue progressively decreased from stage 1 to stage 3 of PD with statistical significance in smokers (267±55 μmolHCLO/ml) (p<0.05) (Table 1).

In serum, FR production was progressively increased from stage 1 to stage 3 of PD. It showed the highest level in stage 3 in both groups, non smokers (371±75 UCarr) (p<0.05) and smokers (410±79 UCarr) (p<0.01). In serum, AOC showed decreasing values from stage 1 to stage 3 of PD, with statistical significance in smokers (292±61 μmolHCLO/ml) (p<0.05) (Table 2).

Compared with the reference values from the control group (338±63 μmolHCLO/ml), AOC of periodontal tissue showed greater reduction in values in stage 3 of PD in both non smokers (290±85 μmolHCLO/ml) and smokers (267±55 μmolHCLO/ml). Compared to controls (342±67 μmolHCLO/ml), though AOC showed similar decrements in serum from stage 3 PD in both non smokers (327±64 μmolHCLO/ml) and smokers (292±61 μmolHCLO/ml), the magnitude of change was lesser than that in periodontal tissue (Figure 2).

### Table 1: OS markers in periodontal tissue in non smokers and smokers with different PD stages

<table>
<thead>
<tr>
<th>Subject groups</th>
<th>Periodontal disease intensity</th>
<th>Number of cases</th>
<th>Free radicals UCarr</th>
<th>Antioxidant capacity μmol HCLO/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy subjects (control group)</td>
<td>/</td>
<td>n=30</td>
<td>220±53</td>
<td>338±63</td>
</tr>
<tr>
<td>PD patients (non smokers)</td>
<td>Stage 1</td>
<td>n=15</td>
<td>323±75</td>
<td>329±77</td>
</tr>
<tr>
<td></td>
<td>Stage 2</td>
<td>n=15</td>
<td>400±71*</td>
<td>298±69</td>
</tr>
<tr>
<td></td>
<td>Stage 3</td>
<td>n=15</td>
<td>440±88*</td>
<td>290±85</td>
</tr>
<tr>
<td>PD patients (smokers)</td>
<td>Stage 1</td>
<td>n=15</td>
<td>396±67*</td>
<td>297±79</td>
</tr>
<tr>
<td></td>
<td>Stage 2</td>
<td>n=15</td>
<td>439±72**</td>
<td>288±53*</td>
</tr>
<tr>
<td></td>
<td>Stage 3</td>
<td>n=15</td>
<td>528±90**</td>
<td>267±55*</td>
</tr>
</tbody>
</table>

* p<0.05; ** p<0.01

### Table 2: OS markers in serum of non smokers and smokers with different PD stages

<table>
<thead>
<tr>
<th>Subject groups</th>
<th>Periodontal inflammation intensity</th>
<th>Number of cases</th>
<th>Free radicals UCarr</th>
<th>Antioxidant capacity μmol HCLO/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy subjects (control group)</td>
<td>/</td>
<td>n=30</td>
<td>293±68</td>
<td>342±67</td>
</tr>
<tr>
<td>PD patients (non smokers)</td>
<td>Stage 1</td>
<td>n=15</td>
<td>295±50</td>
<td>337±73</td>
</tr>
<tr>
<td></td>
<td>Stage 2</td>
<td>n=15</td>
<td>332±63</td>
<td>340±79</td>
</tr>
<tr>
<td></td>
<td>Stage 3</td>
<td>n=15</td>
<td>371±75*</td>
<td>327±64</td>
</tr>
<tr>
<td>PD patients (smokers)</td>
<td>Stage 1</td>
<td>n=15</td>
<td>334±61</td>
<td>330±77</td>
</tr>
<tr>
<td></td>
<td>Stage 2</td>
<td>n=15</td>
<td>385±65*</td>
<td>300±63</td>
</tr>
<tr>
<td></td>
<td>Stage 3</td>
<td>n=15</td>
<td>410±79**</td>
<td>292±61*</td>
</tr>
</tbody>
</table>

* p<0.05; ** p<0.01

**Figure 1:** Free radicals in stage 3 of non smokers and smokers with PD

**Figure 2:** Antioxidant capacity in stage 3 of non smokers and smokers with PD

UCarr

μmolHCLO/ml
pro-oxidant mechanism of cell damage leads to tissue de-
struction either by increased free radical production or by in-
hibited immune system, also initiating cancer risk by a pro-
flammatory profile (26, 27, 28).

CONCLUSION

Based on our results, we may conclude that OS has a
great influence on PD pathogenesis, which may also be a
trigger mechanism leading to a further periodontal dam-
age. This process may be further accelerated by cigarette
smoking, thus revealing the link between nicotine presence

LP in serum of PD patients demonstrated progressively
increasing values from stage 1 to stage 3 of PD. The highest
level of LP observed in stage 3 was significantly greater than
controls in both non smokers (3.9±0.9 μmol/l) (p<0.05) and
smokers (4.1±1.1 μmol/l) (p<0.05) (Table 3).

DISCUSSION

Although FR showed higher values in serum than in
periodontal tissue in healthy subjects, increasing FR pro-
duction towards the severe stage of PD was much more
evident in periodontal tissue in both non smokers and
smokers. This is most likely because intravascular fluid is
more frequently replenished with antioxidant agents such
as albumin, bilirubin, uric acid, glutathione, ascorbic acid,
and ubiquinol, which do not allow rapid FR increase in se-
rum compared to periodontal tissue.

Concerning disease severity, higher the stage of PD, the
more severe OS observed. This relationship was even more
evident in the group of smokers suffering from PD. Thus,
OS was demonstrated by increased FR and decreased AOC
in periodontal tissue and serum of the patient groups,
and also by increased serum LP process. The imbalance
between the antioxidant defence and repair system and pro-
oxidant mechanism of cell damage leads to tissue de-
struction either by increased free radical production or by a
lowered AOC defence (16).

FRs such as superoxide anion, hydrogen peroxide and
hydroxyl radicals, produced by neutrophils, can attack
biological molecules. As an initial product, superoxide
anion, generated by the molecular oxygen reduction un-
der NADPH oxidase increases cell oxygen consumption,
activates several cell surface G proteins and provokes a
cascade of events, resulting in cell damage (17). Hydrox-
yl radicals damage important molecules, such as DNA,
proteins and lipids; hydrogen peroxide is known to cross
nuclear membrane and damages DNA; and superoxide
anion is involved in bone reabsorption. Moreover, hydro-
gen peroxide stimulates phosphorylation of nuclear factor
kappa β (NFκβ) complex and facilitates nuclear transloca-
tion and causes production of proinflammatory cytokines
including interleukin-2 (II-2), interleukin-6 (II-6), inter-
leukin-8 (II-8), β-interferon and tumour necrosis factor-α
(TNF-α). All of these agents are well known as very im-
portant factors in the PD pathogenesis (18). Cigarette
smoking boosts FR production in patients with PD, which
is most evident in the severe stage of disease. This might
be due to increased antioxidant consumption in smokers
which impairs antioxidant body defence and causes OS
progression. Systemic and local MDA as an end product
of LP is increased by smoking and has a strong relation
with the inflammation of periodontal tissue. Concerning
low AOC, decreased activity of antioxidant enzymes such
as superoxide dismutase, glutathione peroxidase and cata-
lase might be caused by smoking. Inflammation is greater
in periodontal tissue of smokers, which can be a cause of
increased metallothionein as a free radical scavenger (19,
20). In the study of Garg N. et al, 2006, in smokers, the
analysed parameters such as LP, superoxide dismutase,
catalase, glutathione and total thiol showed increased OS
proportionally related to the number of cigarettes smoked
day by day (21). Nicotine affects gingival blood flow, cytokine
production, neutrophil and other immune cell function,
as well as connective tissue turnover, all of which can be
responsible for overall effects on periodontal tissues (22,
23). Furthermore, involvement of salivary differed hista-
mine and increased salivary calcium in smokers exacer-
bates PD (24, 25). Antioxidant agents may overcome this
impairment and may attenuate disease progression by
down regulating glutathione detoxification / redox buff-
ering system and by inhibiting key transcription factors,
which lead to bone reabsorption. The factors such as fork-
head box (FoxOs) family members induce the expression of
genes controlling defence against OS and promote cell
survival by inhibiting cyclin in cell cycle. The stage of PD,
linked to smoking, may be a critical marker of a suscep-
tible immune system, also initiating cancer risk by a pro-
oxidant inflammatory profile (26, 27, 28).

<table>
<thead>
<tr>
<th>Subject groups</th>
<th>Periodontal inflammation intensity</th>
<th>Number of cases</th>
<th>Lipid peroxidation (MDA) μmol/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy subjects (control group)</td>
<td>/</td>
<td>n=30</td>
<td>3.5±0.9</td>
</tr>
<tr>
<td>PD patients (non smokers)</td>
<td>Stage 1</td>
<td>n=15</td>
<td>3.4±1.0</td>
</tr>
<tr>
<td></td>
<td>Stage 2</td>
<td>n=15</td>
<td>3.5±1.2</td>
</tr>
<tr>
<td></td>
<td>Stage 3</td>
<td>n=15</td>
<td>3.9±0.9</td>
</tr>
<tr>
<td>PD patients (smokers)</td>
<td>Stage 1</td>
<td>n=15</td>
<td>4.0±1.3*</td>
</tr>
<tr>
<td></td>
<td>Stage 2</td>
<td>n=15</td>
<td>4.2±1.2*</td>
</tr>
<tr>
<td></td>
<td>Stage 3</td>
<td>n=15</td>
<td>4.1±1.1*</td>
</tr>
</tbody>
</table>

* p<0.05;

Table 3: OS markers in serum of non smokers and smokers with different PD stages
and increased FR production. More studies are required to clarify the therapeutic effects of efficient antioxidant agents for PD to arrest further periodontal tissue damage and contribute to better disease outcome.

REFERENCES